<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="142665">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01243658</url>
  </required_header>
  <id_info>
    <org_study_id>OX02</org_study_id>
    <nct_id>NCT01243658</nct_id>
  </id_info>
  <brief_title>&quot;The Effects of Oxytocin on Patients With Borderline Personality Disorder&quot;</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Prof. Dr. Markus Heinrichs</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Freiburg</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RCT. Two substudies (clinical and experimental). Main objective of the trial is to examine
      if oxytocin, compared to placebo shows any additional effect on the therapy achievements
      (outcome) of patients with borderline personality disorder, who receive an in-patient
      standard psychotherapy (Dialectical-behavioral-therapy, Marsha Linehan (2006)).

      Secondary objectives :

      Investigate if oxytocin compared to placebo enhances social trust and emotion recognition in
      patients with borderline personality disorder. Comparison of the effects of Oxytocin on
      patients with BPD and major depression.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2011</start_date>
  <completion_date type="Anticipated">January 2016</completion_date>
  <primary_completion_date type="Actual">August 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>BPD Symptoms</measure>
    <time_frame>BPD Symptoms</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Effects of Oxytocin on Borderline Personality Disorder.</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxytocin</intervention_name>
    <description>Oxytocin</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Gender: Both, male and female

          -  Minimum Age: 18 Years

          -  Maximum Age: 50 Years

          -  Borderline personality disorder or major depression (clinical control group)

          -  Mini Mental Status Test &gt; 27 (capacity to consent)

        Exclusion Criteria:

          -  chronic or acute somatic health problems

          -  Schizophrenia

          -  Bipolar affective disorder

          -  pregnancy

          -  breast feeding

          -  neurological disorder

          -  allergy to antidegradants
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Markus Heinrichs, Prof. Dr.</last_name>
    <role>Study Director</role>
    <affiliation>Institut f체r Psychologie der Univerist채t Freiburg</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nicole Ower, Psychologist</last_name>
    <phone>0049-761-20397743</phone>
    <email>Nicole.ower@psychologie.uni-freiburg.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Albert-Ludwigs-Universit채t-Freiburg</name>
      <address>
        <city>Freiburg</city>
        <state>Baden-W체rtemberg</state>
        <zip>79104</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicole Ower, Psychologist</last_name>
      <phone>0049-761-20397743</phone>
      <email>Nicole.ower@psychologie.uni-freiburg.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <lastchanged_date>December 8, 2014</lastchanged_date>
  <firstreceived_date>November 17, 2010</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Freiburg</investigator_affiliation>
    <investigator_full_name>Prof. Dr. Markus Heinrichs</investigator_full_name>
    <investigator_title>Prof. Dr. Markus Heinrichs</investigator_title>
  </responsible_party>
  <keyword>Oxytocin</keyword>
  <keyword>BPD</keyword>
  <keyword>Borderline</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Personality Disorders</mesh_term>
    <mesh_term>Borderline Personality Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Oxytocin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
